聚二磷酸腺苷核糖聚合酶抑制剂在结直肠癌治疗中的研究进展  

Progress of poly (adenosine diphosphate-ribose) polymerase inhibitors in treatment of colorectal cancer

作　　者：陈智琴 宋海飞 高勇[1] 权明 Chen Zhiqin;Song Haifei;Gao Yong;Quan Ming(Department of Oncology,Dongfang Hospital Affiliated to Tongji University,Shanghai 200123,China)

机构地区：[1]同济大学附属东方医院肿瘤科,上海200123

出　　处：《肿瘤研究与临床》2022年第4期310-313,共4页Cancer Research and Clinic

基　　金：国家自然科学基金(81972280)。

摘　　要：结直肠癌是常见的恶性肿瘤之一,发病率和病死率逐年上升,近年来精准靶向治疗使部分患者获益,但总体预后仍不理想。以BRCA1/2为代表的同源重组修复缺陷相关治疗是近年来的研究热点,伴随着聚二磷酸腺苷核糖聚合酶(PARP)抑制剂在卵巢癌、乳腺癌、胰腺癌等恶性肿瘤中的广泛应用及确切疗效,PARP抑制剂也逐渐应用于结直肠癌。文章就目前PARP抑制剂在结直肠癌治疗中的研究进展进行总结。Colorectal cancer is one of the most common malignant tumors,and its morbidity and mortality increase year by year.In recent years,some patients with colorectal cancer have benefited from precision targeted therapies,but the overall prognosis is still unsatisfactory.Treatment of homologous recombination deficiency represented by BRCA1/2 has become a hot research direction at present.With the wide application and exact curative effect of poly(adenosine diphosphate-ribose)polymerase(PARP)inhibitors in ovarian cancer,breast cancer,pancreatic cancer and other malignant tumors,PARP inhibitors are also gradually being used in colorectal cancer.This review summarizes the current research progress of PARP inhibitors in treatment of colorectal cancer.

关 键 词：结直肠肿瘤 PARP抑制剂 同源重组修复缺陷 治疗结果 

分 类 号：R735.34[医药卫生—肿瘤]